Difference between revisions of "Enasidenib (Idhifa)"
Jump to navigation
Jump to search
m (Jwarner moved page AG-221 to Enasidenib (Idhifa): FDA approval) |
m |
||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
| − | IDH2 | + | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=752247 NCI Drug Dictionary]]: An orally available inhibitor of isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits IDH2 in the mitochondria, which inhibits the formation of 2-hydroxyglutarate (2HG). |
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Acute myeloid leukemia]] | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *8/1/2017: Granted [https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm569482.htm FDA regular approval] "for the treatment of adult patients with relapsed or refractory [[acute myeloid leukemia|acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation]] as detected by an FDA-approved test. | ||
| + | |||
| + | ==Also known as== | ||
| + | AG-221, CC-90007 | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| + | [[Category:Oral medications]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
| + | [[Category:Mutation-specific drugs]] | ||
| + | |||
| + | [[Category:Acute myeloid leukemia medications]] | ||
[[Category:Enzyme inhibitors]] | [[Category:Enzyme inhibitors]] | ||
[[Category:IDH2 inhibitors]] | [[Category:IDH2 inhibitors]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 2017]] | ||
Revision as of 13:35, 2 August 2017
Mechanism of action
From the NCI Drug Dictionary]: An orally available inhibitor of isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits IDH2 in the mitochondria, which inhibits the formation of 2-hydroxyglutarate (2HG).
Diseases for which it is used
History of changes in FDA indication
- 8/1/2017: Granted FDA regular approval "for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.
Also known as
AG-221, CC-90007